Anti-EGFR plus chemotherapy in unselected advanced oesophageal squamous cell carcinoma: less POWERful than expected
Ann Oncol
.
2020 Feb;31(2):161-162.
doi: 10.1016/j.annonc.2019.11.009.
Authors
C Connell
1
,
E C Smyth
2
Affiliations
1
Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
2
Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. Electronic address: elizabeth.smyth2@nhs.net.
PMID:
31959330
DOI:
10.1016/j.annonc.2019.11.009
No abstract available
Publication types
Editorial
Comment
MeSH terms
Cisplatin
ErbB Receptors
Esophageal Neoplasms*
Esophageal Squamous Cell Carcinoma*
Fluorouracil
Humans
Panitumumab
Prospective Studies
Substances
Panitumumab
EGFR protein, human
ErbB Receptors
Cisplatin
Fluorouracil